PTC
GNMK

Petrus Trust Company’s GenMark Diagnostics, Inc GNMK Stock Holding History

Petrus Trust Company’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-31,953
Closed -$154K – 348
2019
Q4 		$154K Buy
+31,953
New +$176K 0.02% 268

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Petrus Trust Company's GNMK Position: Q1 2020 in Review

Petrus Trust Company sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2020, closing a stake of 31,953 shares — an estimated $154K sold.

Petrus Trust Company first reported a position in GNMK in Q4 2019 and held it in 1 quarter. The position peaked at $154K in Q4 2019. 110 funds tracked by Wall St. Rank hold GNMK as of Q1 2020.

  • Petrus Trust Company reported no remaining GenMark Diagnostics, Inc position as of Q1 2020 after selling out during the quarter.
  • Petrus Trust Company sold 31,953 GenMark Diagnostics, Inc shares in Q1 2020, an estimated $154K.
  • Petrus Trust Company first reported a position in GenMark Diagnostics, Inc in Q4 2019 and held it in 1 quarter.
  • Petrus Trust Company's GenMark Diagnostics, Inc position peaked at $154K in Q4 2019.
  • 110 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2020.

Based on Petrus Trust Company's 13F filing for Q1 2020, filed 15 May 2020.